Abstract:Genes influencing opioid use disorder (OUD) biology have been identified via genome-wide association studies (GWAS), gene expression, and network analyses. These discoveries provide opportunities to identifying existing compounds targeting these genes for drug repurposing studies. However, systematically integrating discovery results and identifying relevant available pharmacotherapies for OUD repurposing studies is challenging. To address this, we’ve constructed a framework that leverages existing results and drug databases to identify candidate pharmacotherapies. For this study, two independent OUD related meta-analyses were used including a GWAS and a differential gene expression (DGE) study of post-mortem human brain. Protein-Protein Interaction (PPI) sub-networks enriched for GWAS risk loci were identified via network analyses. Drug databases Pharos, Open Targets, Therapeutic Target Database (TTD), and DrugBank were queried for clinical status and target selectivity. Cross-omic and drug query results were then integrated to identify candidate compounds. GWAS and DGE analyses revealed 3 and 335 target genes (FDR q<0.05), respectively, while network analysis detected 70 genes in 22 enriched PPI networks. Four selection strategies were implemented, which yielded between 72 and 676 genes with statistically significant support and 110 to 683 drugs targeting these genes, respectively. After filtering out less specific compounds or those targeting well-established psychiatric-related receptors ( and ), between 2 and 329 approved drugs remained across the four strategies. By leveraging multiple lines of biological evidence and resources, we identified many FDA approved drugs that target genes associated with OUD. This approach a) allows high-throughput querying of OUD-related genes, b) detects OUD-related genes and compounds not identified using a single domain or resource, and c) produces a succinct summary of FDA approved compounds eligible for efficient expert review. Identifying larger pools of candidate pharmacotherapies and summarizing the supporting evidence bridges the gap between discovery and drug repurposing studies.

Insights into the Mechanisms Underlying Opioid Use Disorder and Potential Treatment Strategies

IUPHAR review: Recent progress in the development of Mu opioid receptor modulators to treat opioid use disorders

Opioid use disorder: current trends and potential treatments

Shared and Divergent Transcriptomic Regulation in Nucleus Accumbens D1 and D2 Medium Spiny Neurons by Cocaine and Morphine

Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date

Opioid Use Disorder: Treatments and Barriers

Personalized medicine and opioid use disorder

Characterization of 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(indole-7-carboxamido)morphinan (NAN) As a Novel Opioid Receptor Modulator for Opioid Use Disorder Treatment

Mechanism of opioid addiction and its intervention therapy: Focusing on the reward circuitry and mu-opioid receptor

The Cholinergic System as a Treatment Target for Opioid Use Disorder

Untangling the complexity of opioid receptor function

[Mechanisms Underlying Opioid Addiction: New Progress].

Pharmacological Characterization of 17-Cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-[(3'-fluoro-4'-pyridyl)acetamido]morphinan (NFP) As a Dual Selective MOR/KOR Ligand with Potential Applications in Treating Opioid Use Disorder.

Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine

Selective review and commentary on emerging pharmacotherapies for opioid addiction.

An emerging multi-omic understanding of the genetics of opioid addiction

The opioid receptors as targets for drug abuse medication

Identifying compounds to treat opiate use disorder by leveraging multi-omic data integration and multiple drug repurposing databases

Oxytocin and opioid addiction revisited: old drug, new applications

The Mechanisms Involved in Morphine Addiction: An Overview

Machine-learning analysis of opioid use disorder informed by MOR, DOR, KOR, NOR and ZOR-based interactome networks